156 related articles for article (PubMed ID: 24939622)
21. Dysregulation of glutamate carboxypeptidase II in psychiatric disease.
Guilarte TR; Hammoud DA; McGlothan JL; Caffo BS; Foss CA; Kozikowski AP; Pomper MG
Schizophr Res; 2008 Feb; 99(1-3):324-32. PubMed ID: 18191545
[TBL] [Abstract][Full Text] [Related]
22. Valproate-Induced Epigenetic Upregulation of Hypothalamic Fto Expression Potentially Linked with Weight Gain.
Zhang H; Lu P; Tang HL; Yan HJ; Jiang W; Shi H; Chen SY; Gao MM; Zeng XD; Long YS
Cell Mol Neurobiol; 2021 Aug; 41(6):1257-1269. PubMed ID: 32500354
[TBL] [Abstract][Full Text] [Related]
23. [Inhibitory effect of VPA on multiple myeloma U266 cell proliferation and regulation of histone acetylation].
Zhu YF; Ye BG; Shen JZ; Lin CM; Lin FA; Shen SF; Xu CB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):638-41. PubMed ID: 20561418
[TBL] [Abstract][Full Text] [Related]
24. Hepatoprotection and lethality rescue by histone deacetylase inhibitor valproic acid in fatal hemorrhagic shock.
Gonzales ER; Chen H; Munuve RM; Mehrani T; Nadel A; Koustova E
J Trauma; 2008 Sep; 65(3):554-65. PubMed ID: 18784568
[TBL] [Abstract][Full Text] [Related]
25. Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis.
Mlcochová P; Plechanovová A; Barinka C; Mahadevan D; Saldanha JW; Rulísek L; Konvalinka J
FEBS J; 2007 Sep; 274(18):4731-41. PubMed ID: 17714508
[TBL] [Abstract][Full Text] [Related]
26. Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs.
Barinka C; Hlouchova K; Rovenska M; Majer P; Dauter M; Hin N; Ko YS; Tsukamoto T; Slusher BS; Konvalinka J; Lubkowski J
J Mol Biol; 2008 Mar; 376(5):1438-50. PubMed ID: 18234225
[TBL] [Abstract][Full Text] [Related]
27. Valproic acid (VPA) reduces sensorimotor gating deficits and HDAC2 overexpression in the MAM animal model of schizophrenia.
Bator E; Latusz J; Radaszkiewicz A; Wędzony K; Maćkowiak M
Pharmacol Rep; 2015 Dec; 67(6):1124-9. PubMed ID: 26481530
[TBL] [Abstract][Full Text] [Related]
28. Pentyl-4-yn-VPA, a histone deacetylase inhibitor, ameliorates deficits in social behavior and cognition in a rodent model of autism spectrum disorders.
Foley AG; Cassidy AW; Regan CM
Eur J Pharmacol; 2014 Mar; 727():80-6. PubMed ID: 24486700
[TBL] [Abstract][Full Text] [Related]
29. Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells.
Aztopal N; Erkisa M; Erturk E; Ulukaya E; Tokullugil AH; Ari F
Chem Biol Interact; 2018 Jan; 280():51-58. PubMed ID: 29225137
[TBL] [Abstract][Full Text] [Related]
30. Valproic acid stimulates proliferation of glial precursors during cortical gliogenesis in developing rat.
Lee HJ; Dreyfus C; DiCicco-Bloom E
Dev Neurobiol; 2016 Jul; 76(7):780-98. PubMed ID: 26505176
[TBL] [Abstract][Full Text] [Related]
31. Biochemical characterization of human glutamate carboxypeptidase III.
Hlouchová K; Barinka C; Klusák V; Sácha P; Mlcochová P; Majer P; Rulísek L; Konvalinka J
J Neurochem; 2007 May; 101(3):682-96. PubMed ID: 17241121
[TBL] [Abstract][Full Text] [Related]
32. Valproic acid increases NO production via the SH-PTP1-CDK5-eNOS-Ser(116) signaling cascade in endothelial cells and mice.
Cho DH; Park JH; Joo Lee E; Jong Won K; Lee SH; Kim YH; Hwang S; Ja Kwon K; Young Shin C; Song KH; Jo I; Han SH
Free Radic Biol Med; 2014 Nov; 76():96-106. PubMed ID: 25150199
[TBL] [Abstract][Full Text] [Related]
33. Glutamate carboxypeptidase II does not process amyloid-β peptide.
Sedlák F; Šácha P; Blechová M; Březinová A; Šafařík M; Šebestík J; Konvalinka J
FASEB J; 2013 Jul; 27(7):2626-32. PubMed ID: 23525279
[TBL] [Abstract][Full Text] [Related]
34. Maternal inflammation leads to impaired glutamate homeostasis and up-regulation of glutamate carboxypeptidase II in activated microglia in the fetal/newborn rabbit brain.
Zhang Z; Bassam B; Thomas AG; Williams M; Liu J; Nance E; Rojas C; Slusher BS; Kannan S
Neurobiol Dis; 2016 Oct; 94():116-28. PubMed ID: 27326668
[TBL] [Abstract][Full Text] [Related]
35. Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme.
Alt J; Stathis M; Rojas C; Slusher B
FASEB J; 2013 Jul; 27(7):2620-5. PubMed ID: 23525278
[TBL] [Abstract][Full Text] [Related]
36. Valproic acid-mediated neuroprotection in retinal ischemia injury via histone deacetylase inhibition and transcriptional activation.
Zhang Z; Qin X; Tong N; Zhao X; Gong Y; Shi Y; Wu X
Exp Eye Res; 2012 Jan; 94(1):98-108. PubMed ID: 22143029
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of 68Ga-Glutamate Carboxypeptidase II Ligand Positron Emission Tomography for Clinical Molecular Imaging of Atherosclerotic Plaque Neovascularization.
Derlin T; Thiele J; Weiberg D; Thackeray JT; Püschel K; Wester HJ; Aguirre Dávila L; Larena-Avellaneda A; Daum G; Bengel FM; Schumacher U
Arterioscler Thromb Vasc Biol; 2016 Nov; 36(11):2213-2219. PubMed ID: 27609368
[TBL] [Abstract][Full Text] [Related]
38. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives.
Eikel D; Lampen A; Nau H
Chem Res Toxicol; 2006 Feb; 19(2):272-8. PubMed ID: 16485903
[TBL] [Abstract][Full Text] [Related]
39. Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid.
Qiao L; Schaack J; Shao J
Endocrinology; 2006 Feb; 147(2):865-74. PubMed ID: 16282359
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic modifications in valproic acid-induced teratogenesis.
Tung EW; Winn LM
Toxicol Appl Pharmacol; 2010 Nov; 248(3):201-9. PubMed ID: 20705080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
